Zhitong Finance App News, Hutchmed (00013.HK) announced that its subsidiary HUTCHMED (Shanghai) Limited (HUTCHMED) Limited (HUTCHMED) has reached an exclusive development and licensing agreement with a subsidiary of GSK plc (“GlaxoSmithKline”), granting the GlaxoSmithKline subsidiary the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau, and Taiwan. Clinical development will first focus on colorectal cancer, pancreatic cancer, and lung cancer indications. The agreement includes a $110 million down payment and potential development, registration and commercialization milestone payments, totaling $1,295 million, plus royalties based on net sales. This is the world's first (first-in-class) antibody-targeted conjugate drug (ATTC) candidate, using a highly selective, highly active KRAS (Kirsten rat sarcoma) small molecule inhibitor as a payload and conjugated with an anti-epidermal growth factor receptor (EGFR) antibody. ATTC is guided by antibodies, so that the potent cell-killing payload can selectively focus on tumor tissue and exert activity.

Zhitong Finance App News, Hutchmed (00013.HK) announced that its subsidiary HUTCHMED (Shanghai) Limited (HUTCHMED) Limited (HUTCHMED) has reached an exclusive development and licensing agreement with a subsidiary of GSK plc (“GlaxoSmithKline”), granting the GlaxoSmithKline subsidiary the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau, and Taiwan. Clinical development will first focus on colorectal cancer, pancreatic cancer, and lung cancer indications. The agreement includes a $110 million down payment and potential development, registration and commercialization milestone payments, totaling $1,295 million, plus royalties based on net sales. This is the world's first (first-in-class) antibody-targeted conjugate drug (ATTC) candidate, using a highly selective, highly active KRAS (Kirsten rat sarcoma) small molecule inhibitor as a payload and conjugated with an anti-epidermal growth factor receptor (EGFR) antibody. ATTC is guided by antibodies, so that the potent cell-killing payload can selectively focus on tumor tissue and exert activity.